Generic placeholder image

Current Bioactive Compounds

Editor-in-Chief

ISSN (Print): 1573-4072
ISSN (Online): 1875-6646

Research Article

Anticancer Activity of Novel 1,3,4-oxadiazole Derivatives against PARP-1 Inhibitors: An In-silico Approach

Author(s): Praveen Kumar Patel, Preeya Negi, Sowmiya Arun, Kaviarasan Lakshmanan, Gowramma Byran*, Kalirajan Rajagopal and Gomathi Swaminathan

Volume 20, Issue 4, 2024

Published on: 06 October, 2023

Article ID: e250823220345 Pages: 18

DOI: 10.2174/1573407219666230825103621

Price: $65

conference banner
Abstract

Background: Nuclear enzyme poly (ADP-ribose) polymerase-1 (PARP-1) controls the cell cycle, DNA repair, transcription, and replication processes. In this study, olaparib and rucaparib have been taken as standard drugs for comparison of results. As per previous research data, 1,3,4-Oxadiazole moiety has multidirectional biological activity and shows high activity against cancer.

Objective: This study aimed to carry out the in silico ligand-based screening for the identification of hits for PARP1 inhibitors bearing 1,3,4-thiadiazole derivatives using Schrodinger suite 2022-1 and to perform MMGBSA and molecular dynamics simulation for lead molecules.

Methods: A total of 32 derivatives of 1,3,4-Oxadiazole were designed with four different acids: phenoxy acetic acid, 1-Naphthoxy acetic acid, 2-Naphthoxy acetic acid, and piperonylic acid. Molecular docking (XP) studies were performed between 4ZZZ.pdb and the designed analogues, and the binding affinity values lay in the range of -8.52 to -3.52 kcal/mol. 2D interactions between the protein and the ligand were observed. Based on the binding affinity values and ADMET results, top 10 analogues were selected for performing MM-GBSA.

Results: The dG-bind score of the top compounds varied from -2.30 to -60.67 kcal/mol, and analogue D4 was selected for MD simulation studies for 100ns. Results of Molecular dynamics (MD) studies showed that D4 interacted with amino acid residues, and the ligand-protein interaction stabilized from 58-90ns. The in silico study's findings suggested that the chemicals A1, A3, B1, B2, B3, B4, C1, C6, D1, and D4 might be significantly active against breast cancer with potential therapeutic benefits and are likely to be useful after further development.

Conclusion: In conclusion, numerous molecules exhibit a high affinity for PARP-1 when derived from 1,3,4-oxadiazole. The in silico study's findings suggested that the chemicals A1, A3, B1, B2, B3, B4, C1, C6, D1, and D4 might be significantly active against breast cancer with potential therapeutic benefits and are likely to be useful after further development.

Keywords: PARP-1, cancer, 1, 3, 4-Oxadiazole, molecular docking, molecular dynamics simulation and anti-cancer.

Graphical Abstract
[1]
Ofn, S. Cancer statistics registrations: Registrations of cancer diagnosed in 2004; National Statistics: England, 2010, p. 38.
[2]
Meacham, C.E.; Morrison, S.J. Tumour heterogeneity and cancer cell plasticity. Nature, 2013, 501(7467), 328-337.
[http://dx.doi.org/10.1038/nature12624] [PMID: 24048065]
[3]
Fisher, R.; Pusztai, L.; Swanton, C. Cancer heterogeneity: Implications for targeted therapeutics. Br. J. Cancer, 2013, 108(3), 479-485.
[http://dx.doi.org/10.1038/bjc.2012.581] [PMID: 23299535]
[4]
Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2016. CA Cancer J. Clin., 2016, 66(1), 7-30.
[http://dx.doi.org/10.3322/caac.21332] [PMID: 26742998]
[5]
Schottenfeld, D.; Fraumeni, J.F., Jr Eds.; Cancer epidemiology and prevention Oxford University Press: United Kingdom, 2006.
[http://dx.doi.org/10.1093/acprof:oso/9780195149616.001.0001]
[6]
Yoo, K.Y.; Shin, H.R. Cancer Epidemiology and Prevention. Korean J Epidemiol., 2003, 25(1), 1-5.
[PMID: 11850580]
[7]
Aizawa, K.; Liu, C.; Tang, S.; Veeramachaneni, S.; Hu, K.Q.; Smith, D.E.; Wang, X.D. Tobacco carcinogen induces both lung cancer and non-alcoholic steatohepatitis and hepatocellular carcinomas in ferrets which can be attenuated by lycopene supplementation. Int. J. Cancer, 2016, 139(5), 1171-1181.
[http://dx.doi.org/10.1002/ijc.30161] [PMID: 27116542]
[8]
Poon, S.; McPherson, J.R.; Tan, P.; Teh, B.; Rozen, S.G. Mutation signatures of carcinogen exposure: Genome-wide detection and new opportunities for cancer prevention. Genome Med., 2014, 6(3), 24.
[http://dx.doi.org/10.1186/gm541] [PMID: 25031618]
[9]
Trafialek, J; Kolanowski, W Dietary exposure to meat-related carcinogenic substances: Is there a way to estimate the risk? Int. J. Food Sci. Nutr., 2014, 65(36), 774-780.
[10]
Cumberbatch, MG; Cox, A; Teare, D Catto, JW Contemporary Occupational Carcinogen Exposure and Bladder Cancer: A Systematic Review and Meta-analysis. JAMA Oncol., 2015, 1(9), 1282-90.
[http://dx.doi.org/10.1001/jamaoncol.2015.3209]
[11]
Antwi, S.O.; Eckert, E.C.; Sabaque, C.V.; Leof, E.R.; Hawthorne, K.M.; Bamlet, W.R.; Chaffee, K.G.; Oberg, A.L.; Petersen, G.M. Exposure to environmental chemicals and heavy metals, and risk of pancreatic cancer. Cancer Causes Control, 2015, 26(11), 1583-1591.
[http://dx.doi.org/10.1007/s10552-015-0652-y] [PMID: 26293241]
[12]
Parkin, D.M. The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer, 2006, 118(12), 3030-3044.
[http://dx.doi.org/10.1002/ijc.21731] [PMID: 16404738]
[13]
Tabrez, S.; Zughaibi, T.A.; Hoque, M.; Suhail, M.; Khan, M.I.; Khan, A.U. Targeting glutaminase by natural compounds: Structure-based virtual screening and molecular dynamics simulation approach to suppress cancer progression. Molecules, 2022, 27(15), 5042-5051.
[http://dx.doi.org/10.3390/molecules27155042] [PMID: 35956989]
[14]
Gowramma, B.; Negi, P.; Lakshmanan, K.; Patel, P.K.; Kalirajan, R. An update on Poly(ADP-ribose) polymerase I – A brief review. Mini Rev. Med. Chem., 2023, 23.
[http://dx.doi.org/10.2174/1389557523666230221145844] [PMID: 36824002]
[15]
Wang, J.; Li, H.; He, G.; Chu, Z.; Peng, K.; Ge, Y.; Zhu, Q.; Xu, Y. Discovery of Novel Dual Poly(ADP-ribose)polymerase and Phosphoinositide 3-Kinase Inhibitors as a Promising Strategy for Cancer Therapy. J. Med. Chem., 2020, 63(1), 122-139.
[http://dx.doi.org/10.1021/acs.jmedchem.9b00622] [PMID: 31846325]
[16]
Franzese, E.; Centonze, S.; Diana, A.; Lombardi, A.; Carlino, F.; Guerrera, L.P.; De Vita, F.; Caraglia, M.; Pignata, S.; Ciardiello, F.; Orditura, M. Genomic profile and BRCA-1 promoter methylation status in BRCA Mutated Ovarian Cancer: New insights in predictive biomarkers of olaparib response. Front. Oncol., 2019, 9(9), 1289-1296.
[http://dx.doi.org/10.3389/fonc.2019.01289] [PMID: 31850198]
[17]
Papeo, G.; Posteri, H.; Borghi, D.; Busel, A.A.; Caprera, F.; Casale, E.; Ciomei, M.; Cirla, A.; Corti, E.; D’Anello, M.; Fasolini, M.; Forte, B.; Galvani, A.; Isacchi, A.; Khvat, A.; Krasavin, M.Y.; Lupi, R.; Orsini, P.; Perego, R.; Pesenti, E.; Pezzetta, D.; Rainoldi, S.; Riccardi-Sirtori, F.; Scolaro, A.; Sola, F.; Zuccotto, F.; Felder, E.R.; Donati, D.; Montagnoli, A. Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1 H -isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy. J. Med. Chem., 2015, 58(17), 6875-6898.
[http://dx.doi.org/10.1021/acs.jmedchem.5b00680] [PMID: 26222319]
[18]
Morris, G.M.; Lim-Wilby, M. Molecular Docking. Methods Mol. Biol., 2008, 443, 365-382.
[http://dx.doi.org/10.1007/978-1-59745-177-2_19] [PMID: 18446297]
[19]
Santhi, N.; Aishwarya, S. Insights from the molecular docking of withanolide derivatives to the target protein PknG from Mycobacterium tuberculosis. Bioinformation, 2011, 7(1), 1-4.
[http://dx.doi.org/10.6026/97320630007001] [PMID: 21904430]
[20]
Politi, A.; Durdagi, S.; Moutevelis-Minakakis, P.; Kokotos, G.; Mavromoustakos, T. Development of accurate binding affinity predictions of novel renin inhibitors through molecular docking studies. J. Mol. Graph. Model., 2010, 29(3), 425-435.
[http://dx.doi.org/10.1016/j.jmgm.2010.08.003] [PMID: 20855222]
[21]
Gudipati, S.; M, R.; Mankad, A.; Pandya, H.; Jasrai, Y.T. Molecular docking based screening of Noggin inhibitors. Bioinformation, 2018, 14(1), 015-020.
[http://dx.doi.org/10.6026/97320630014015] [PMID: 29497255]
[22]
Kalirajan, R.; Pandiselvi, A.; Gowramma, B.; Balachandran, P. In-silico Design, ADMET Screening, MM-GBSA Binding Free Energy of Some Novel Isoxazole Substituted 9-Anilinoacridines as HER2 Inhibitors Targeting Breast Cancer. Curr. Drug Res. Rev., 2019, 11(2), 118-128.
[http://dx.doi.org/10.2174/2589977511666190912154817] [PMID: 31513003]
[23]
Iwaloye, O.; Elekofehinti, O.O.; Momoh, A.I.; Babatomiwa, K.; Ariyo, E.O. In silico molecular studies of natural compounds as possible anti-Alzheimer’s agents: Ligand-based design. Netw. Model. Anal. Health Inform. Bioinform., 2020, 9(1), 54-67.
[http://dx.doi.org/10.1007/s13721-020-00262-7]
[24]
Naresh, P.; Selvaraj, A.; Shyam Sundar, P.; Murugesan, S.; Sathianarayanan, S.; Namboori, P K, K.; Jubie, S. Targeting a conserved pocket (n-octyl-β-D-glucoside) on the dengue virus envelope protein by small bioactive molecule inhibitors. J. Biomol. Struct. Dyn., 2022, 40(11), 4866-4878.
[http://dx.doi.org/10.1080/07391102.2020.1862707] [PMID: 33345726]
[25]
William, L. Temperature and size dependence for Monte Carlo simulations of TIP4P water. Mol. Phys., 2023, 56(6), 1381-1392.
[26]
Lawrence, C.P.; Skinner, J.L. Flexible TIP4P model for molecular dynamics simulation of liquid water. Chem. Phys. Lett., 2003, 372(5-6), 842-847.
[http://dx.doi.org/10.1016/S0009-2614(03)00526-8]
[27]
Harder, E.; Damm, W.; Maple, J.; Wu, C.; Reboul, M.; Xiang, J.Y.; Wang, L.; Lupyan, D.; Dahlgren, M.K.; Knight, J.L.; Kaus, J.W.; Cerutti, D.S.; Krilov, G.; Jorgensen, W.L.; Abel, R.; Friesner, R.A. OPLS3: A force field providing broad coverage of drug-like small molecules and proteins. J. Chem. Theory Comput., 2016, 12(1), 281-296.
[http://dx.doi.org/10.1021/acs.jctc.5b00864] [PMID: 26584231]
[28]
Genheden, S.; Ryde, U. The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert Opin. Drug Discov., 2015, 10(5), 449-461.
[http://dx.doi.org/10.1517/17460441.2015.1032936] [PMID: 25835573]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy